Combination of Direct Antivirals May Be Key to Curing Hepatitis C, University of Illinois, Oakland University, And Los Alamos National Laboratory Study

Physorg -- Using probabilistic and viral dynamic models, researchers at the University of Illinois at Chicago, Oakland University and Los Alamos National Laboratory predict why rapid resistance emerges in hepatitis C virus and show that a combination of drugs that can fight three or more mutated strains may be needed to eradicate the virus from the body. They compared their model with data from a clinical trial of the new direct-acting antiviral medication telaprevir.

Back to news